Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference

Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano
 
New data from clinical trials of TT11 and TT11X to be featured in oral and poster presentations

 
SINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced two presentations featuring clinical data from the company’s autologous CD30.CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy (TT11X) will be featured at the 17th International Conference on Malignant Lymphoma taking place from June 13-17, 2023, at Lugano, Switzerland.
 
TT11, is Tessa’s autologous CD30.CAR-T therapy currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients. A poster providing first peak into data from this combination study will be presented at ICML, 2023.
 
TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform. An abstract highlighting updated data from the ongoing Phase 1 study of TT11X (BESTA) in CD30-positive lymphomas will be featured in an oral podium presentation at ICML, 2023.
 
Details of the two presentations are as follows:
17th International Conference on Malignant Lymphoma, Lugano
Abstract Number: 388 (Poster) 
Abstract Title: Combined autologous CD30.CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study) 
Session Date: Friday, 16 June (even-numbered posters)
Time: 12:30 to 13:00
Abstract Number: 47 (Podium)
Abstract Title: Off-the-shelf CD30.CAR-modified Epstein-Barr Virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL)
Session: SESSION 7 - NEW CAR-T CELL APPROACHES
Session Date: Thursday, 15 June 
Time: 15:30 to 16:45

About Tessa Therapeutics  
Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s autologous CD30-CAR-T therapy TT11, is currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency. Tessa is also advancing an allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state-of-the-art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com. 
 
Tessa Therapeutics Investor Contact 
Wilson W. Cheung 
Chief Financial Officer 
wcheung@tessacell.com 
Tessa Therapeutics Media Contact 
Tiberend Strategic Advisors, Inc. 
Bill Borden 
+1-732-910-1620 
bborden@tiberend.com 
Dave Schemelia 
+1-609-468-9325 
dschemelia@tiberend.com